Elsevier

Bone

Volume 42, Issue 4, April 2008, Pages 788-797
Bone

FGF23 is elevated in Gambian children with rickets

https://doi.org/10.1016/j.bone.2007.11.014Get rights and content

Abstract

Objectives

Fibroblast growth factor 23 (FGF23) is a phosphaturic factor that is elevated in several diseases associated with hypophosphatemia and rickets. Rickets in the absence of vitamin D deficiency has been reported in African and Asian populations with a low calcium intake but the definition of risk factors has proved elusive. The aim of the study was to characterize the biochemical profile and measure FGF23 in a series of Gambian children who had presented with rickets of unknown etiology and a plasma 25-hydroxyvitamin D (25OHD) above the range typical of vitamin D-deficiency rickets.

Methods

The 46 patients (30 males, 16 females) had bone deformities typical of rickets and were 1.1–16.4 years old (geometric mean, 3.4 years). Active rickets (on radiographs and/or elevated plasma alkaline phosphatase) was present in 28%. Plasma 25-hydroxyvitamin D was above 20 nmol/l in all patients. Concentrations of plasma FGF23, phosphate and other relevant biochemical analytes were measured in stored samples of fasting, early morning plasma and compared with those measured in samples collected from local children and stored under similar conditions.

Results

The rickets patients had lower plasma phosphate, lower 25-hydroxyvitamin D, higher 1,25-dihydroxyvitamin D and elevated total alkaline phosphatase than local children. Those with active rickets had raised parathyroid hormone concentration. The patients had significantly higher FGF23 concentration than local children (geometric mean (− 1SD, + 1SD, range) RU/ml: 367 (87, 1552, 46–7052, n = 39) vs 51 (23, 112, 3–130, n = 30), p  0.001). At presentation, the majority (74%) had an FGF23 concentration that was above the range seen in local children, some grossly so (up to 50-fold). There was no significant difference in FGF23 concentration between those with active rickets and the other patients. Plasma phosphate was significantly and inversely correlated with FGF23 concentration. Some clinical improvements were noted after 6–12 months, during which time calcium and vitamin D had been prescribed, but FGF23 remained elevated in many patients.

Conclusions

These data suggest that perturbations of phosphate and FGF23 regulation may be implicated in the pathogenesis of calcium-deficiency rickets in Africa and Asia.

Introduction

Fibroblast growth factor 23 (FGF23) is a recently discovered humoral factor involved in extracellular phosphate homeostasis [1], [2], [3]. It affects renal phosphate handling, by inhibiting phosphate reabsorption and thus promoting phosphate excretion. Elevated plasma concentrations of FGF23, resulting from an increased production or decreased inactivation of the protein, are associated with hypophosphatemia, phosphate wasting and impaired bone mineralization in a variety of syndromes, including tumor-induced osteomalacia (TIO) [4], fibrous dysplasia of bone [5], and possibly autosomal dominant hypophosphatemic rickets (ADHR) [6], [7], and X-linked hypophosphatemic rickets (XLH) [4]. Recent evidence suggest that FGF23 is part of a homeostatic system for phosphate and vitamin D [1], [3], [8], [9], circulating at low concentrations in healthy adults and children [4], [10], [11].

Rickets in children is generally associated with vitamin D deficiency and is most common in infancy [12]. However, in recent years, there have been reports from Africa and Asia of rickets in older children with normal or near-normal plasma concentrations of 25-hydroxyvitamin D (25OHD) [13], [14], [15], [16]. The incidence of rickets in some areas is high, with, for example, as many as 9% of young children in the central plateau region of Nigeria having clinical features suggestive of rickets [13]. These children live in populations where calcium intake is typically very low and close to the biological requirement for normal bone growth [15], [17], [18], and there is good evidence that affected children respond to calcium treatment alone [15], [18], [19]. This suggests that dietary calcium deficiency may be the primary cause, possibly combined with an underlying genetic predisposition [20]. However, to date, the exact etiology of the disease remains elusive and attempts to define risk factors in some studies have proved unsuccessful, suggesting there may be other contributory factors [12].

The common finding of a low plasma phosphate (PO4) in severe cases of calcium-deficiency rickets [15], [16], [18] suggests that perturbations of phosphate regulation may play a role in the pathogenesis of this disease. This paper describes an investigation of plasma FGF23 concentration, and its relationship to plasma PO4, in a series of children who presented at two clinics in The Gambia, West Africa, with clinical rickets and 25OHD in the normal range.

Section snippets

Background

The Gambia is situated in sub-Saharan West Africa, latitude 13°N. The climate is hot and dry, with a single rainy season from July to October. Tropical sunshine is abundant all year and there are no cultural restrictions on dress or lifestyle that prevent regular sunshine exposure. Demand breast-feeding of infants is universal. Complementary foods are introduced at 3–6 months and breast-feeding is stopped at about 2 years. The calcium content of the local diet, including breast-milk, is low.

At presentation

The 46 patients ranged in age from 1.1 to 16.4 years. The age distribution was positively skewed with a geometric mean (− 1SD, + 1SD) of 3.4 (1.9, 6.4) years. More boys presented than girls (30 M, 65%; 16 F, 35%).

Thirteen patients (28%) had active rickets, as defined by a total ALP > 960 U/l (n = 7), a Thacher Score > 1.5 (n = 1) or both (n = 5). Of those patients with bone deformity but without active rickets (the non-active rickets group), the majority had one or more X-ray signs of healed rickets or

Discussion

Bone deformities associated with rickets and osteomalacia have been reported from a number of African and Asian countries among children without overt vitamin D deficiency [13], [14], [15], [16], [27]. Such children are characterized by lower 25OHD, elevated 1,25(OH)2D and, in severe cases, by lower plasma PO4, lower plasma Ca and raised PTH compared with local controls [13], [14], [15], [16], [18], [28]. Dietary calcium deficiency has been identified as a likely cause [14], [15], [27] and both

Acknowledgments

This paper is dedicated to the memory of the late Dr Bakary Dibba, who first drew our attention to bone deformities in Gambian children and initiated the investigations that led to this paper. We are indebted to Dr Tom Thacher, Dept of Family Medicine, Jos University Teaching Hospital, Jos, Nigeria and Dr Phil Fischer, Dept of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA, for their expert advice and input into conceptual development. We would like to thank the

References (46)

  • T. Shimada et al.

    FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa

    Biochem Biophys Res Commun

    (2004)
  • H.K.K. Saito et al.

    Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1a,25-dihydroxyvitamin D3 production

    J Biol Chem

    (2003)
  • T.D. Thacher et al.

    Early response to vitamin D2 in children with calcium deficiency rickets

    J Pediatr

    (2006)
  • G.J. Strewler

    Phos, Phex and FGF: mysteries of phosphate homeostasis revealed — or still hidden

    BoneKEy-Osteovision

    (2004)
  • C. Silve et al.

    Is FGF23 the long sought after phosphaturic factor phosphatonin?

    Nephrol Dial Transplant

    (2002)
  • T. Berndt et al.

    The phosphatonins and the regulation of phosphorus homeostasis

    BoneKEy-Osteovision

    (2005)
  • K.B. Jonsson et al.

    Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia

    N Engl J Med

    (2003)
  • M. Riminucci et al.

    FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting

    J Clin Invest

    (2003)
  • T. Shimada et al.

    Mutant FGF-23 responsible for autosomal-dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo

    Endocrinol

    (2002)
  • E.A. Imel et al.

    FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets

    J Bone Miner Res

    (2007)
  • T. Shimada et al.

    Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism

    J Clin Invest

    (2004)
  • O.I. Kolek et al.

    1alpha, 25-dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport

    Am J Physiol Gastrointest Liver Physiol

    (2005)
  • T.J. Weber et al.

    Serum FGF23 levels in normal and disordered phosphorus homeostasis

    J Bone Miner Res

    (2003)
  • Cited by (0)

    Conflict of interest: None of the authors has a conflict of interest with respect to the study reported in this paper.

    View full text